Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 69 million follow-on offering of UroGen Pharma Ltd. on the NASDAQ Global Market. UroGen Pharma is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.
Jefferies and Cowen and Company acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering and Ladenburg Thalmann & Co. and National Securities Corporation acted as co-managers for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner).
